The first jab of Modernsay (NASDAQ: MRNA) two-stroke coronavirus vaccine has not made it into the arms of the millions it will eventually receive, but the company is already planning to measure the effectiveness of an enhancer.
In a presentation at this year’s annual JP Morgan Healthcare conference, Moderna, said it plans to do so in a clinical trial with participants in earlier studies on the vaccine, mRNA-1273. Contact with potential participants has already begun and it is planned to start the study in July.
Image Source: Getty Images.
“From what we’ve seen so far, I think our expectation is that the vaccination will last you at least a year,” Tal Zaks, chief medical officer of Moderna, said during the conference. “To the extent that you require a boost survey, we will make a sound recommendation, and it will require us to get the data.”
In the planned study, Moderna will try to determine what the immune response generated by the booster shot is, CEO Stephane Bancel said during the event.
The timing is right for a follow-up study, as the participants in the first clinical trials of the vaccine are closer to their one-year anniversary of receiving the booster. They got the first shot in mid-March 2020.
Moderna is one of two coronavirus vaccines authorized by the US Food and Drug Administration for emergency use. The implementation of mRNA-1273 and Pfizer/BioNTechThe BNT162b2 of two shots is also sluggish. The numbers of patients receiving the first dose remain alarmingly low.